NCT02743429Unknown2 期
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
University Medicine Greifswald2 个研究点 分布在 2 个国家目标入组 40 人开始时间: 2015年3月27日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Anti-tumour activity of ch14.18/CHO continuous infusion
研究概览
简要总结
In this trial, monoclonal anti-Disialoganglioside GD2 (GD2) antibody ch14.18/CHO will be assessed for the treatment of patients with relapsed or refractory neuroblastoma. The antibody is used as a single agent applied in a new treatment schedule associated with less side effects.
详细描述
The Treatment with ch14.18 antibody has demonstrated efficacy in patients with neuroblastoma. However the treatment is associated with an on target side effect, i.e. neuropathic pain. This requires coadministration of intravenous morphine.
In this clinical Trial we will evaluate a less toxic treatment regimen consisting of continuous longterm Infusion (LTI) of ch14.18/CHO administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle). Patients may receive up to five 35-day cycles in absence of signs of progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 12 months and ≤ 21 years of age at the time of study entry
- •Diagnosis of neuroblastoma according to the INSS criteria
- •Tumour burden controlled by conventional therapy (except patients with early minimal bone marrow relapse) fulfilling one of the following criteria:
- •Primary refractory patients with stage 4 disease
- •Relapse after primary stage 4 disease
- •Disseminated relapse after primary localized neuroblastoma.
- •Measurable and/or evaluable disease in any of the following sites (skeletal lesions, soft tissue lesions, lymph nodes and/or primary tumour site and/or bone marrow) as measured by mIBG scan, CT, MRI and/or immunocytology
- •Life expectancy of at least 12 weeks.
- •Performance status greater or equal to 70% (Lansky Score or Karnofsky)
- •Consent to the placement of a central venous line, if one has not already been placed
- •Off any standard or experimental treatment for at least two weeks prior to start of immunotherapy (Day 1 of cycle 1) and fully recovered from the short-term major toxic effects
- •No immediate requirements for palliative chemotherapy, radiotherapy or surgery
- •At least 2 weeks from any tumour surgery and fully recovered from any post-surgical complications
- •HIV sero-negative
- •Neither active nor chronic-replicative Hepatitis B infection
- •Females of childbearing potential must have a negative pregnancy test and must agree to use an effective birth control method during the whole study duration including the last FU visit.
- •Female patients who are lactating must agree to stop breast-feeding.
- •Patient may have had prior CNS metastases, provided the following criteria are all met:
- •The patient's CNS disease has been previously treated.
- •The patient's CNS disease has been clinically stable for four weeks prior to starting this study (assessment must be made clinically and by CT or MRI).
- •The patient is off steroids for four weeks prior to starting trial treatment and will not require them during the course of the study.
- •Patients with seizure disorders may be enrolled if well controlled on anticonvulsants and if no seizures have occurred within a 6 week period prior to starting trial treatment
- •All patients and/or their parents or legal guardians must sign a written informed consent.
- •Laboratory testing:
- •Shortening fraction of ≥ 30% on Echocardiogram.
- •FEV1 and FVC > 60% of the predicted by pulmonary function tests. Children unable to do PFTs should have no dyspnoea at rest and a pulse oximetry > 94% in room air.
- •Adequate bone marrow function as defined by ANC >0.5 10^9/L, platelets ≥ 20 10^9/L and haemoglobin > 8.0 g/dL
- •Adequate liver function, as defined by an ALT or AST < 5 x normal and a total bilirubin < 1.0 mg/dL.
- •Adequate renal function, as defined by a serum creatinine <1.5 mg/dL or a creatinine clearance or radioisotope GFR of > 60 mL/minute/1.73 m².
排除标准
- •Progressive disease at the time of inclusion into the study.
- •ADA positivity due to previous treatment with an anti-GD2 antibody (e.g. ch14.18/SP2/0, ch14.18/CHO).
- •Previous treatment with ch14.18/CHO in this study.
- •e) Requirement, or likely requirement, for corticosteroids or other immunosuppressive drugs.
- •f) Concurrent treatment with any non-trial anticancer therapies. g) Patients with hypersensitivity against one component of the investigational product or against mouse proteins.
- •h) Female patients of childbearing potential if pregnant, nursing, or not using effective contraception during the treatment period, as the potential effects of ch14.18 on the fetus have not been determined.
研究组 & 干预措施
Long term infusion of ch14.18/CHO
Experimental
10 day continuous Infusion of ch14.18/CHO.
干预措施: dinutuximab beta (Drug)
结局指标
主要结局
Anti-tumour activity of ch14.18/CHO continuous infusion
时间窗: 2 years
The response rate in patients with measurable/evaluable disease (skeletal lesions, soft tissue lesions, lymph nodes and/or primary tumour site and bone marrow) as measured by Metaiodobenzylguanidine scan (MIBG), Computed tomography (CT), Magnetic Resonance Imaging (MRI) and/or immunocytology at the end of the study.
次要结局
- Immunophenotyping(2 years)
- Safety and tolerability(2 years)
- Progression-Free Survival(5 years)
- Antibody dependent cellular cytotoxicity (ADCC)(2 years)
- Whole Blood Test (WBT)(2 years)
- Cytokines(2 years)
- Clearance (CL)(2 years)
- Volume distribution at steady state (Vdss)(2 years)
- half-life time (t1/2)(2 years)
- Immunogenicity(2 years)
- Area Under the Curve (AUC)(2 years)
- Complement dependent cytotoxicity (CDC)(2 years)
- mean residence time (MRT)(2 years)
- Maximum Plasma Concentration (Cmax) and Minimum Plasma Concentration (Cmin)(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk NeuroblastomaLocalized Resectable NeuroblastomaLocalized Unresectable NeuroblastomaNeurotoxicity SyndromePainRegional NeuroblastomaStage 4 NeuroblastomaStage 4S NeuroblastomaNCT01418495National Cancer Institute (NCI)12
进行中（未招募）
1 期
PHASE II STUDY OF CH14.18/CHO IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMAPRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMAMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000588-42-DEMedical University Greifswald40
进行中（未招募）
1 期
PHASE II STUDY OF CH14.18/CHO IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMAEUCTR2014-000588-42-ATMedical University Greifswald40
已完成
2 期
A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 DiabetesType 2 DiabetesNCT01427699Janssen Research & Development, LLC7
进行中（未招募）
2 期
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaRefractory Non-Small Cell Lung CancerNCT06015724Georgetown University19